HK1118716A1 - Method and composition for treating central nervous system disorders - Google Patents
Method and composition for treating central nervous system disordersInfo
- Publication number
- HK1118716A1 HK1118716A1 HK08110344.4A HK08110344A HK1118716A1 HK 1118716 A1 HK1118716 A1 HK 1118716A1 HK 08110344 A HK08110344 A HK 08110344A HK 1118716 A1 HK1118716 A1 HK 1118716A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- composition
- nervous system
- central nervous
- system disorders
- treating central
- Prior art date
Links
- 208000015114 central nervous system disease Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64700805P | 2005-01-27 | 2005-01-27 | |
| PCT/JP2006/301704 WO2006080549A2 (en) | 2005-01-27 | 2006-01-26 | Method and composition for treating central nervous system disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1118716A1 true HK1118716A1 (en) | 2009-02-20 |
Family
ID=36740907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK08110344.4A HK1118716A1 (en) | 2005-01-27 | 2008-09-18 | Method and composition for treating central nervous system disorders |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US8202909B2 (xx) |
| EP (2) | EP2332545A1 (xx) |
| JP (1) | JP5147404B2 (xx) |
| KR (1) | KR101354771B1 (xx) |
| CN (1) | CN101146541B (xx) |
| AR (1) | AR055846A1 (xx) |
| AU (1) | AU2006209072B2 (xx) |
| BR (1) | BRPI0607084A2 (xx) |
| CA (1) | CA2595898C (xx) |
| DK (1) | DK1841433T3 (xx) |
| ES (1) | ES2375082T3 (xx) |
| HK (1) | HK1118716A1 (xx) |
| IL (1) | IL184578A (xx) |
| NO (1) | NO340257B1 (xx) |
| NZ (1) | NZ556710A (xx) |
| PL (1) | PL1841433T3 (xx) |
| PT (1) | PT1841433E (xx) |
| RU (1) | RU2440338C2 (xx) |
| TW (1) | TWI384988B (xx) |
| WO (1) | WO2006080549A2 (xx) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI225398B (en) * | 1999-07-14 | 2004-12-21 | R Tech Ueno Ltd | Composition for treatment of external secretion disorders |
| US20080207759A1 (en) * | 2007-02-27 | 2008-08-28 | Sucampo Ag | Method for protecting mitochondria |
| NZ583203A (en) * | 2007-07-19 | 2011-10-28 | Sucampo Ag | Pharmaceutical composition comprising 11-deoxy-prostaglandin compound and method for stabilizing the compound |
| US8871752B2 (en) * | 2008-02-19 | 2014-10-28 | Sucampo Ag | Method for modulating stem cell growth |
| US9084815B2 (en) | 2009-09-16 | 2015-07-21 | Sucampo Ag | Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor |
| CN103180306B (zh) * | 2010-10-15 | 2015-05-20 | 神隆(昆山)生化科技有限公司 | 鲁比前列酮的制备方法 |
| EP2667875A4 (en) * | 2011-01-24 | 2014-07-30 | Inceptum Res & Therapeutics Inc | COMPOSITIONS COMPRISING PROSTAGLANDIN FOR THE TREATMENT OF NEUROPSYCHIATRIC DISEASES |
| CN103781482A (zh) * | 2011-04-19 | 2014-05-07 | 苏坎波公司 | 用于调节细胞因子活性的方法 |
| JP6193230B2 (ja) * | 2011-08-05 | 2017-09-06 | スキャンポ・アーゲーＳｕｃａｍｐｏ ＡＧ | 統合失調症の処置方法 |
| WO2014159679A1 (en) | 2013-03-12 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for using lubiprostone to absorb fluid from the subretinal space |
| EP3209637B1 (en) * | 2014-10-21 | 2019-05-08 | Universitat de les Illes Balears | 2-hydroxy-triacylglycerol compounds for use in treating disease |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1120243A (en) | 1970-03-09 | 1968-07-17 | Samuelsson Bengt | Improvements in or relating to unsaturated carboxylic acid derivatives and the manufacture thereof |
| BE786215A (fr) | 1971-07-14 | 1973-01-15 | American Cyanamid Co | Nouveaux composes apparentes aux prostaglandines naturelles et procedesde leur preparation |
| ZA764727B (en) * | 1975-09-02 | 1977-07-27 | Upjohn Co | Prostanoic acid derivatives |
| SU845774A3 (ru) | 1976-04-20 | 1981-07-07 | Фармиталия Карло Эрба С.П.А. (Фирма) | Способ получени 13,14-дегидро-11-дЕзОКСипРОСТАглАНдиНОВ |
| US4131738A (en) * | 1977-07-05 | 1978-12-26 | The Upjohn Company | 6-Hydroxy-PGE1 compounds |
| CA1322749C (en) | 1987-01-28 | 1993-10-05 | Ryuzo Ueno | Prostaglandins of the d series, and tranquilizers and soporifics containing the same |
| US5166174A (en) | 1987-01-28 | 1992-11-24 | K.K. Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti-ulcers containing same |
| US5221763A (en) | 1987-04-30 | 1993-06-22 | R-Tech Ueno, Ltd. | Prostaglandins of the F series |
| US5317032A (en) | 1987-10-02 | 1994-05-31 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Prostaglandin cathartic |
| CA2030345C (en) * | 1989-11-22 | 1998-12-08 | Ryuji Ueno | Use of 15-keto-prostaglandin compound for improvement of encephalic function |
| CA2037009C (en) | 1990-02-26 | 1998-01-27 | Ryuji Ueno | 15-dehydroxy-16-oxoprostaglandins |
| CA2039420C (en) | 1990-04-04 | 1996-12-10 | Ryuji Ueno | Treatment of cataract with 15-keto-prostaglandin compounds |
| JPH04187637A (ja) * | 1990-11-21 | 1992-07-06 | Ueno Seiyaku Oyo Kenkyusho:Kk | 記憶改善剤 |
| JPH07113012B2 (ja) | 1991-01-29 | 1995-12-06 | 株式会社アールテック・ウエノ | 新規１５−ケト−プロスタグランジン類 |
| JP3183615B2 (ja) * | 1994-06-03 | 2001-07-09 | 株式会社アールテック・ウエノ | 肝・胆道系疾患処置剤 |
| CA2150287C (en) | 1994-06-03 | 2004-08-10 | Ryuji Ueno | Agent for treating hepato-biliary diseases |
| US6242485B1 (en) | 1996-06-10 | 2001-06-05 | R-Tech Ueno | Endothelin antagonist |
| ES2310013T3 (es) * | 1997-11-28 | 2008-12-16 | Sucampo Ag | Uso de compuestos de 15-ceto-prostaglandina e como antagonistas de endotelina. |
| JP3703004B2 (ja) | 1998-07-15 | 2005-10-05 | 小野薬品工業株式会社 | ５−チア−ω−置換フェニル−プロスタグランジンＥ誘導体 |
| WO2000051978A1 (en) * | 1999-03-01 | 2000-09-08 | Nitromed, Inc. | Nitrosated and nitrosylated prostaglandins, compositions and metods of use |
| TWI225398B (en) * | 1999-07-14 | 2004-12-21 | R Tech Ueno Ltd | Composition for treatment of external secretion disorders |
| TWI284535B (en) * | 2000-03-24 | 2007-08-01 | Sucampo Ag | Apoptosis inhibitor |
| US6414016B1 (en) | 2000-09-05 | 2002-07-02 | Sucampo, A.G. | Anti-constipation composition |
| US20040224995A1 (en) * | 2003-05-09 | 2004-11-11 | University Of North Texas Health Science Center At Fort Worth | Neuroprotective effects of PPARy agonists against cellular oxidative insults |
| CN1214794C (zh) * | 2003-09-08 | 2005-08-17 | 秦正红 | 前列腺素a1在制备治疗脑缺血性中风疾病的药物中的用途 |
-
2006
- 2006-01-26 RU RU2007132081/04A patent/RU2440338C2/ru active
- 2006-01-26 EP EP11155203A patent/EP2332545A1/en not_active Withdrawn
- 2006-01-26 CA CA2595898A patent/CA2595898C/en not_active Expired - Fee Related
- 2006-01-26 ES ES06712847T patent/ES2375082T3/es active Active
- 2006-01-26 TW TW095103028A patent/TWI384988B/zh not_active IP Right Cessation
- 2006-01-26 BR BRPI0607084-1A patent/BRPI0607084A2/pt not_active Application Discontinuation
- 2006-01-26 DK DK06712847.0T patent/DK1841433T3/da active
- 2006-01-26 PL PL06712847T patent/PL1841433T3/pl unknown
- 2006-01-26 CN CN2006800094248A patent/CN101146541B/zh not_active Expired - Fee Related
- 2006-01-26 EP EP06712847A patent/EP1841433B1/en active Active
- 2006-01-26 NZ NZ556710A patent/NZ556710A/en not_active IP Right Cessation
- 2006-01-26 JP JP2007535160A patent/JP5147404B2/ja not_active Expired - Fee Related
- 2006-01-26 WO PCT/JP2006/301704 patent/WO2006080549A2/en active Application Filing
- 2006-01-26 US US11/339,495 patent/US8202909B2/en active Active
- 2006-01-26 PT PT06712847T patent/PT1841433E/pt unknown
- 2006-01-26 AU AU2006209072A patent/AU2006209072B2/en not_active Ceased
- 2006-01-26 KR KR1020077019366A patent/KR101354771B1/ko active IP Right Grant
- 2006-01-26 AR ARP060100290A patent/AR055846A1/es not_active Application Discontinuation
-
2007
- 2007-07-12 IL IL184578A patent/IL184578A/en active IP Right Grant
- 2007-08-24 NO NO20074332A patent/NO340257B1/no not_active IP Right Cessation
-
2008
- 2008-09-18 HK HK08110344.4A patent/HK1118716A1/xx not_active IP Right Cessation
-
2012
- 2012-05-14 US US13/470,377 patent/US20120225938A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR101354771B1 (ko) | 2014-01-22 |
| JP2008528440A (ja) | 2008-07-31 |
| US20060194880A1 (en) | 2006-08-31 |
| US20120225938A1 (en) | 2012-09-06 |
| CN101146541B (zh) | 2012-04-11 |
| WO2006080549A3 (en) | 2007-07-05 |
| TW200642690A (en) | 2006-12-16 |
| RU2440338C2 (ru) | 2012-01-20 |
| CN101146541A (zh) | 2008-03-19 |
| RU2007132081A (ru) | 2009-03-10 |
| IL184578A0 (en) | 2007-10-31 |
| PL1841433T3 (pl) | 2012-07-31 |
| AU2006209072B2 (en) | 2011-02-24 |
| EP1841433B1 (en) | 2011-11-30 |
| DK1841433T3 (da) | 2012-01-16 |
| NO340257B1 (no) | 2017-03-27 |
| PT1841433E (pt) | 2012-02-01 |
| WO2006080549A2 (en) | 2006-08-03 |
| KR20070107065A (ko) | 2007-11-06 |
| NZ556710A (en) | 2010-08-27 |
| US8202909B2 (en) | 2012-06-19 |
| TWI384988B (zh) | 2013-02-11 |
| CA2595898C (en) | 2015-04-28 |
| BRPI0607084A2 (pt) | 2009-08-04 |
| CA2595898A1 (en) | 2006-08-03 |
| IL184578A (en) | 2015-02-26 |
| NO20074332L (no) | 2007-10-17 |
| EP1841433A2 (en) | 2007-10-10 |
| AU2006209072A1 (en) | 2006-08-03 |
| EP2332545A1 (en) | 2011-06-15 |
| AR055846A1 (es) | 2007-09-12 |
| ES2375082T3 (es) | 2012-02-24 |
| JP5147404B2 (ja) | 2013-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1118716A1 (en) | Method and composition for treating central nervous system disorders | |
| HK1111884A1 (en) | Method and composition for treating inflammatory disorders | |
| HK1101140A1 (en) | Compositions and methods for treating neurological disorders | |
| IL179766A0 (en) | Compositions and methods using same for treating neurodegenerative disorders | |
| IL180342A0 (en) | Compositions and methods for treating eye disorders and conditions | |
| EP2083857A4 (en) | METHOD FOR TREATING INTERFERENCE IN CONNECTION WITH MICA | |
| EP1603548A4 (en) | COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS | |
| EP1651164A4 (en) | COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISORDERS | |
| IL186450A0 (en) | Methods for treating anxiety related disorders | |
| EP2170309A4 (en) | METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES | |
| IL179864A0 (en) | Compounds and methods for treating seizure and paroxysmal disorders | |
| IL188988A0 (en) | Methods for preventing and treating metabolic disorders and new pyrazole-o-glycoside derivatives | |
| HUE039108T2 (hu) | Készítmények és eljárások szembetegségek kezelésére | |
| IL185861A0 (en) | Method and composition for treating mucosal disorders | |
| GB0617734D0 (en) | Method of treating peripheral nerve disorders | |
| IL191168A0 (en) | Compositions and methods for treating cns disorders | |
| IL193697A0 (en) | Methods for treating cognitive and other disorders | |
| IL180732A0 (en) | Method for treating nervous system disorders and conditions | |
| ZA200700578B (en) | Method for treating nervous system disorders and conditions | |
| EP1898921A4 (en) | COMPOSITIONS AND METHODS FOR TREATING SLEEP DISORDERS | |
| ZA200708543B (en) | Methods for treating anxiety related disorders | |
| ZA200700580B (en) | Method for treating nervous system disorders and conditions | |
| EP1942909A4 (en) | METHODS OF TREATING RESPIRATORY DISORDERS | |
| EP1755637A4 (en) | METHODS FOR PREVENTING OR TREATING BONE DISEASES | |
| ZA200708408B (en) | Method and composition for treating mucosal disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20210126 |